A detailed history of Parallel Advisors, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 412 shares of CYTK stock, worth $22,536. This represents 0.0% of its overall portfolio holdings.

Number of Shares
412
Previous 479 13.99%
Holding current value
$22,536
Previous $25,000 16.0%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$51.22 - $60.16 $3,431 - $4,030
-67 Reduced 13.99%
412 $21,000
Q2 2024

Aug 08, 2024

BUY
$47.86 - $75.05 $6,891 - $10,807
144 Added 42.99%
479 $25,000
Q1 2024

May 06, 2024

BUY
$63.75 - $108.06 $191 - $324
3 Added 0.9%
335 $23,000
Q4 2023

Feb 09, 2024

BUY
$26.88 - $83.49 $1,155 - $3,590
43 Added 14.88%
332 $27,000
Q3 2023

May 20, 2024

BUY
$29.46 - $36.61 $8,130 - $10,104
276 Added 2123.08%
289 $8,000
Q3 2023

Nov 13, 2023

BUY
$29.46 - $36.61 $8,130 - $10,104
276 Added 2123.08%
289 $8,000
Q2 2023

May 20, 2024

SELL
$32.62 - $40.75 $10,503 - $13,121
-322 Reduced 96.12%
13 $0
Q2 2023

Aug 04, 2023

BUY
$32.62 - $40.75 $424 - $529
13 New
13 $0
Q4 2022

Feb 03, 2023

BUY
$35.77 - $51.11 $357 - $511
10 New
10 $0
Q2 2022

Aug 01, 2022

SELL
$33.93 - $48.92 $237 - $342
-7 Closed
0 $0
Q1 2022

Apr 28, 2022

BUY
$29.74 - $46.0 $208 - $322
7 New
7 $0
Q2 2020

Jul 16, 2020

SELL
$11.15 - $24.64 $535 - $1,182
-48 Closed
0 $0
Q1 2020

Apr 27, 2020

BUY
$8.75 - $16.3 $420 - $782
48 New
48 $0
Q4 2017

Feb 13, 2018

SELL
$7.25 - $15.65 $8,700 - $18,780
-1,200 Closed
0 $0
Q3 2017

Nov 15, 2017

BUY
$12.0 - $15.0 $14,400 - $18,000
1,200 New
1,200 $14,000
Q3 2017

Nov 14, 2017

SELL
$12.0 - $15.0 $20,400 - $25,500
-1,700 Closed
0 $0
Q2 2017

Aug 07, 2017

BUY
N/A
1,700
1,700 $24,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $5.15B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.